MEI Pharma Inc (FRA:MMI0)

€ 4.2 0 (0%) Market Cap: 29.12 Mil Enterprise Value: -15.19 Mil PE Ratio: 1.14 PB Ratio: 0.61 GF Score: 46/100

Q4 2023 MEI Pharma Inc Earnings Call Transcript
Sep 26, 2023

€4.2

Earnings
Infinity Pharmaceuticals Inc and MEI Pharma Inc Merger Agreement Call - Pre-recorded Transcript
Jun 19, 2023
Infinity Pharmaceuticals Inc and MEI Pharma Inc Merger Agreement Call Transcript
Feb 23, 2023
MEI Pharma Inc Annual Shareholders Meeting Transcript
Jan 05, 2023
Q4 2022 MEI Pharma Inc Earnings Call Transcript
Sep 08, 2022

€9.08 (-0.87%)

Earnings
MEI Pharma Inc Zandelisib Program Update Webcast Transcript
Mar 24, 2022
MEI Pharma Inc Annual Shareholders Meeting Transcript
Dec 16, 2021
MEI Pharma Inc Zandelisib Phase 2 TIDAL Study Data Webcast Transcript
Nov 30, 2021
Q4 2021 MEI Pharma Inc Earnings Call Transcript
Sep 02, 2021

€46.96 (+2.18%)

Earnings
MEI Pharma Inc ASCO Investor and Analyst Call Transcript
Jun 10, 2021
MEI Pharma Inc at H C Wainwright Global Life Sciences Conference (Virtual) - Pre-Recorded Transcript
Mar 09, 2021
MEI Pharma Inc at H C Wainwright BioConnect Conference (Virtual) Transcript
Jan 11, 2021
MEI Pharma Inc Annual Shareholders Meeting Transcript
Dec 16, 2020
MEI Pharma Inc at Evercore ISI HealthCONx Conference Transcript
Dec 03, 2020
MEI Pharma Inc at Stifel Virtual Healthcare Conference Transcript
Nov 16, 2020
Q4 2020 MEI Pharma Inc Earnings Call Transcript
Sep 09, 2020

€43.6 (+5.83%)

Earnings
MEI Pharma Inc Post-ASCO Virtual Scientific Program Investor and Analyst Presentation Transcript
Jun 02, 2020
MEI Pharma, Inc. - Special Call Transcript
Apr 14, 2020
MEI Pharma Inc Investor and Analyst Event - A New Chapter in PI3Kd Inhibition to Treat B-cell Malignancies Transcript
Oct 04, 2019
Q4 2019 MEI Pharma Inc Earnings Call Transcript
Aug 28, 2019

€28.33 (-0.76%)

Earnings

MEI Pharma, Inc. - Special Call Transcript

Apr 14, 2020 / 12:00PM GMT

Release Date Price: €45.2 (+61.43%)

Transcript

Operator

Good morning, and welcome to the MEI Pharma conference call for the ME-401 Global License, Development and Commercialization Agreement. Please be advised that the call is being recorded at the company's request.

At this time, I would like to turn the call over to David Walsey, MEI's Vice President, Investor Relations and Corporate Communications. Please proceed.

David A. Walsey

MEI Pharma, Inc. - VP of IR & Corporate Communications

Thank you. Good morning, everyone, and thank you for joining us.

Earlier today, we announced that MEI Pharma and Kyowa Kirin Co., Ltd. entered into a global license, development and commercialization agreement to further develop and commercialize MEI's ME-401. On today's call, we will provide an overview of and commentary on the agreement. We will then open the call to your questions.

Before we get started, I want to call your attention to the fact that this conference call may contain certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.